Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes

Laboratory Investigation

Volumn 91, Issue 9, 2011, Pages 1291-1297

  Kao, Yu Hsun ^a   Cheng, Chen Chuan ^b   Chen, Yao Chang ^c   Chung, Cheng Chih ^d   Lee, Ting I ^a,d   Chen, Shih Ann ^e,f   Chen, Yi Jen ^a,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

heart failure; hydralazine; intracellular calcium; methylation; sarcoplasmic reticulum Ca2+ ATPase

Indexed keywords

DNA METHYLTRANSFERASE 1; HYDRALAZINE; INDO 1; RNA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DEMETHYLATION; DRUG MECHANISM; FLUORESCENCE; GENE EXPRESSION; HEART MUSCLE CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; CALCIUM; CELL LINE; DNA; DNA METHYLATION; HOMEOSTASIS; HYDRALAZINE; MICE; MOLECULAR SEQUENCE DATA; MYOCARDIUM; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 80052275311     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.92     Document Type: Article

References (27)

1. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-784.
2. Zarain-Herzberg A, Afzal N, Elimban V, et al. Decreased expression of cardiac sarcoplasmic reticulum Ca(2+)-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem 1996; 163-164:285-290.
3. Inesi GPA, Pilankatta R. The Ca2+ ATPase of cardiac sarcoplasmic reticulum: physiological role and relevance to diseases. Biochem Biophys Res Commun 2008;369:182-187.
4. Prunier F, Kawase Y, Gianni D, et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 2008;118:614-624.
5. Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008;16: 1026-1032. (Pubitemid 351737066)
6. Muller OJ, Lange M, Rattunde H, et al. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res 2003; 59:380-389. (Pubitemid 37272032)
7. Kao YH, Chen YC, Cheng CC, et al. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 2010;38: 217-222.
8. Kox M, Pickkers P. Poison to the heart. Crit Care Med 2010;38:331-332.
9. Moran AE, Cooper RS, Fitzgibbons TP, et al. Isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2005;352: 1041-1043. (Pubitemid 40349510)
10. Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the African American heart failure trial. Am J Cardiol 2005;96:37i-43i. (Pubitemid 41437922)
11. Daiber A, Mulsch A, Hink U, et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol 2005;96:25i-36i. (Pubitemid 41437921)
12. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membranebound NADH oxidase. A new action for an old drug. J Clin Invest 1996;98:1465-1470. (Pubitemid 26322073)
13. Chuang JC, Yoo CB, Kwan JM, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-20-deoxycytidine. Mol Cancer Ther 2005;4:1515-1520. (Pubitemid 41556433)
14. Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140:2197-2200. (Pubitemid 18098475)
15. Singh N, Duenas-Gonzalez A, Lyko F, et al. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. Chem Med Chem 2009;4:792-799.
16. Arce C, Segura-Pacheco B, Perez-Cardenas E, et al. Hydralazine target: from blood vessels to the epigenome. J Transl Med 2006;4:10.
17. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004;286:H823-H829. (Pubitemid 38248592)
18. Grimm D, Elsner D, Schunkert H, et al. Development of heart failure following isoproterenol administration in the rat: role of the reninangiotensin system. Cardiovasc Res 1998;37:91-100. (Pubitemid 28122620)
19. Chu A, Fill M, Stefani E, et al. Cytoplasmic Ca2+ does not inhibit the cardiac muscle sarcoplasmic reticulum ryanodine receptor Ca2+ channel, although Ca(2+)-induced Ca2+ inactivation of Ca2+ release is observed in native vesicles. J Membr Biol 1993;135:49-59. (Pubitemid 23224371)
20. Münch G, Bö lck B, Karczewski P, et al. Evidence for calcineurinmediated regulation of SERCA 2a activity in human myocardium. J Mol Cell Cardiol 2002;34:321-334. (Pubitemid 37162424)
21. Wongcharoen W, Chen YC, Chen YJ, et al. Effects of a Na+/Ca2+ exchanger inhibitor on pulmonary vein electrical activity and ouabain-induced arrhythmogenicity. Cardiovasc Res 2006;70: 497-508.
22. Davia K, Bernobich E, Ranu HK, et al. SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol 2001;33:1005-1015. (Pubitemid 32545334)
23. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008;51: 1112-1119. (Pubitemid 351374774)
24. Adachi T, Weisbrod RM, Pimentel DR, et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004;10:1200-1207. (Pubitemid 39540436)
25. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003;9:1596-1603. (Pubitemid 36554581)
26. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005;5:44.
27. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-1538. (Pubitemid 47365487)